ArticleAnnals of surgical oncology2026
NUP62 Elevates USP10 Expression and Promotes Tamoxifen Resistance of Breast Cancer by Deubiquitinating ERα.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer (BRCA) continues to be a major global health challenge around the world. Overcoming endocrine resistance remains one of the most significant challenges in the global fight against the disease. This study investigates the function of nucleoporin 62 (NUP62) in BRCA progression and evaluates its potential as a therapeutic target. MATERIALS AND
methodsAnalysis of clinical breast tumor specimens and ERα-positive cell lines revealed that NUP62 expression was significantly upregulated in BRCA, especially in ERα-positive subtypes. In ERα-positive BRCA, high NUP62 levels were strongly linked to inferior survival and served as a robust indicator of adverse prognosis.
resultsThrough in vitro functional assays, NUP62 was shown to facilitate proliferation, invasion, migration, and the epithelial-mesenchymal transition (EMT) in ERα-positive BRCA cells. Mechanistic studies identified that NUP62 promotes deubiquitinase USP10 transcription. Subsequently, USP10 binds to ERα, resulting in enhanced ERα protein stability and the activation of downstream oncogenic signaling. Notably, NUP62 depletion restored tamoxifen sensitivity in endocrine-resistant BRCA cells by compromising ERα stability.
conclusionsThis work establishes NUP62 as a prognostic marker, revealing its dual function in promoting ERα-positive tumorigenesis and conferring endocrine resistance. These findings suggest that therapeutic targeting of NUP62 could be a viable strategy to enhance tamoxifen response and combat resistance in ERα-positive breast cancer.
Indexed as
Identifiers
41501594What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.